XNASITCI
Market cap10bUSD
Jan 10, Last price
94.87USD
1D
14.91%
1Q
25.22%
Jan 2017
528.69%
IPO
374.35%
Name
Intra-Cellular Therapies Inc
Chart & Performance
P/E
—
P/S
21.66
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.88%
Rev. gr., 5y
299.17%
Revenues
464m
+86.40%
Net income
-140m
L-45.49%
CFO
-124m
L-54.03%
Earnings
Feb 20, 2025
Profile
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
IPO date
Jan 31, 2014
Employees
561
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 464,370 86.40% | 249,132 204.91% | |||||||
Cost of revenue | 623,751 | 513,940 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (159,381) | (264,808) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 636 | 6 | |||||||
Tax Rate | |||||||||
NOPAT | (160,017) | (264,814) | |||||||
Net income | (139,674) -45.49% | (256,256) -9.81% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 17,810 | 455,159 | |||||||
BB yield | -0.26% | -9.15% | |||||||
| Debt | |||||||||
Debt current | 7,224 | 4,567 | |||||||
Long-term debt | 30,264 | 35,515 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (460,453) | (551,823) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (124,199) | (270,186) | |||||||
CAPEX | (269) | (778) | |||||||
Cash from investing activities | 105,541 | (128,373) | |||||||
Cash from financing activities | 17,810 | 455,159 | |||||||
FCF | (145,766) | (316,306) | |||||||
| Balance | |||||||||
Cash | 497,941 | 591,905 | |||||||
Long term investments | |||||||||
Excess cash | 474,722 | 579,448 | |||||||
Stockholders' equity | (1,617,046) | (1,481,667) | |||||||
Invested Capital | 2,229,020 | 2,157,778 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 95,882 | 94,047 | |||||||
Price | 71.62 35.34% | 52.92 1.11% | |||||||
Market cap | 6,867,049 37.98% | 4,976,950 17.03% | |||||||
EV | 6,406,596 | 4,425,127 | |||||||
EBITDA | (158,853) | (264,152) | |||||||
EV/EBITDA | |||||||||
Interest | 7,376 | ||||||||
Interest/NOPBT | |||||||||